Navigation Links
HUYA Bioscience Announces Strategic Alliance With Abbott on Drug and Biomarker Development Candidates From China
Date:4/21/2009

Collaboration will leverage HUYA's growing Chinese bioscience network

SAN DIEGO, April 21 /PRNewswire/ -- HUYA Bioscience International, a leader in US/China pharmaceutical co-development, today announced an agreement with Abbott to identify and pursue proprietary preclinical and clinical drug candidates that originate in China.

Abbott will gain access to HUYA's growing Chinese bioscience network comprising premier companies, universities, government research institutions and bioparks throughout the country. HUYA has agreements in place with many of these organizations whereby HUYA has ongoing exclusive access to compounds and biologics in a variety of indications. HUYA is currently evaluating and following the progress of more than 600 lead, preclinical and clinical drug candidates.

"China has an extremely rich pool of drug candidates, which we are able to tap through our extensive network of partners," said Mireille Gingras, PhD, President and CEO of HUYA. "We've been effective in leveraging those relationships to the mutual benefit of our partners in the West and in China, and we're looking forward to a productive collaboration with Abbott."

HUYA's model is based on long-term relationships with its Chinese partners and this provides a continuous source of compounds, unlike a single compound strategy. Once a compound is licensed, the ongoing exchange of expertise and data lowers risk and facilitates rapid and efficient clinical development in both China and the West.

HUYA currently has two clinical stage drugs licensed from China in the therapeutic areas of Cardiovascular and Oncology for development in the West.

HUYA's innovative model benefits partners in the West and China

HUYA was one of the first companies to recognize China's potential to help meet the global need for pre-clinical and clinical stage compounds for the drug development process. HUYA identifies and licenses highly promising pre-clinical and clinical stage compounds in China and provides access to those compounds to partners in the West. Likewise, HUYA provides a valuable bridge to Western development for its partners in China. HUYA's Chinese partners retain development and marketing rights in China with the expectation that both parties will benefit from the research and development collaboration.

One of the key differentiators of HUYA's approach is the assembly of a high-level team of scientific and clinical advisors for each new compound. The team collaborates with its Chinese partners to discuss and design pre-clinical tests and clinical trials as the compounds enter the U.S. development process, speeding the process and mitigating risk. HUYA's global team of advisors includes Benedict Lucchesi, MD, PhD, Peter R. Kowey, MD, Dennis Roy, MD, Jefferson L. Anderson, MD, Eric J. Topol, MD, Stanley Nattel, MD, Anthony Tolcher, MD, Alex Adjei, MD, PhD, Patricia LoRusso, DO and Michael Robertson, MD.

"HUYA has forged highly productive relationships with its Chinese partners, which sets up the potential for clinical development and new treatment options in several diseases," said Eric Topol, Chief Academic Officer, Scripps Health, San Diego, CA.

About HUYA

HUYA is a leader in U.S./China pharmaceutical co-development with four strategic offices in China, a broad Chinese compound portfolio, and a significant number of exclusive agreements with premier Chinese biotech centers. HUYA has joint headquarter offices in San Diego, CA, and Shanghai. Additional information about the company is available at www.huyabio.com.

Contact:

    USA:
    Jan Tuttleman, PhD
    Vice President, Marketing
    HUYA Bioscience International, LLC
    (858) 798-8800
    jtuttleman@huyabio.com

    China:
    Li Zhu, PhD
    VP China Operations
    HUYA Bioscience International, LLC
    86 (21) 51323312

Media Contact:

    Juliet Travis
    (510) 452-3771
    juliet@travispr.com


'/>"/>
SOURCE HUYA Bioscience International
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Biosciences Launches Next-Generation Protein Characterization System
2. Solidus Bioscience Protect their Research and Improve Efficiency With Amphora's PatentSafe Solution
3. Cell Biosciences Announces Publication in Nature Medicine
4. Cell Biosciences Closes $10 Million Series C Financing
5. SAFC Biosciences(R) Expands Media Capability for Chinese Hamster Ovary (CHO) Cell Lines
6. SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free
7. Neurocrine Biosciences to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
8. Catalyst Biosciences Expands Scientific Advisory Board With Leading Experts in Protease Therapeutic Discovery and Development
9. WaferGen Biosystems, ImmuneRegen BioSciences and University of Texas Southwestern Medical Center to Collaborate on Novel Wound Healing Research
10. Three Firms, Two Training Programs Garner Greater Baltimore Committees 2009 Bioscience Awards
11. PURE Bioscience Schedules Second Quarter 2009 Financial Results Conference Call for March 12, 2009 at 1:30 P.M. PDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... San Diego, CA (PRWEB) , ... May 26, ... ... assay development and manufacturing company, today announced several positive developments that position the ... As a result of the transaction, Craig F. Kinghorn has been appointed ...
(Date:5/25/2016)... ... May 25, 2016 , ... Founder of the Fitzmaurice Hand ... and surgery of the hand by the National Board of Physicians and Surgeons, ... and beyond in his pursuit of providing the most comprehensive, effective treatment for ...
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven Pharmaceutical Holding Company ... granted the company’s orphan drug designation request covering BHV-4157 for the treatment of ... the FDA. , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder that ...
(Date:5/23/2016)... ... May 23, 2016 , ... The need for blood donations in South Texas and across ... South Texas Blood & Tissue Center, blood donations are on the decline. In fact, donations ... are down 21 percent in South Texas in the last four years alone. , There ...
Breaking Biology Technology:
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
Breaking Biology News(10 mins):